Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 13Active not recruiting 6Recruiting 4Terminated 3Withdrawn 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3

Conditions

Lung Neoplasms 5Carcinoma, Non-Small-Cell Lung 4Squamous Cell Carcinoma of Head and Neck 3Ovarian Neoplasms 3Neoplasm Metastasis 3Fallopian Tube Neoplasms 3Sezary Syndrome 2Recurrence 2Neoplasms 2Mycosis Fungoides 2Lymphoma, Non-Hodgkin 2Hematologic Neoplasms 2Carcinoma, Renal Cell 2Breast Neoplasms 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Thrombocytosis 1Soft Tissue Neoplasms 1Sarcoma 1Respiratory Distress Syndrome 1Radiation Pneumonitis 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pneumonia 1

Interventions

Carboplatin 44Paclitaxel 43liposomal doxorubicin 23Topotecan 19Gemcitabine 18pembrolizumab 17Cyclophosphamide 17Bevacizumab 16Cisplatin 12niraparib 9olaparib 8fludarabine 7Taxes 7Docetaxel 7aldesleukin 6Nivolumab 6Doxorubicin 61-dodecylpyridoxal 6oregovomab 5fludarabine phosphate 5Peripheral Blood Stem Cell Transplantation 5Filgrastim 5rucaparib 4durvalumab 4avelumab 4Surgical Procedures, Operative 4Melphalan 4Ipilimumab 4Interleukin-2 4Etoposide 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Ovarian Neoplasms × Disulfides × Clear all
NCT02364713 2025-12-11

MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer

Mayo Clinic

Phase 2 Terminated
17 enrolled 14 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04019288 2025-06-11

AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

M.D. Anderson Cancer Center

Phase 1/2 Terminated
12 enrolled 13 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02923739 2024-03-13

Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

M.D. Anderson Cancer Center

Phase 2 Terminated
9 enrolled 9 charts
Gynecologic

Brenner Tumor, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡